TY - JOUR
T1 - Early machine learning prediction of hospitalized patients at low risk of respiratory deterioration or mortality in community-acquired pneumonia
T2 - Derivation and validation of a multivariable model
AU - Odeyemi, Yewande E.
AU - Lal, Amos
AU - Barreto, Erin F.
AU - Lemahieu, Allison M.
AU - Yadav, Hemang
AU - Gajic, Ognjen
AU - Schulte, Phillip
N1 - Publisher Copyright:
© 2023 Odeyemi et al.
PY - 2024/3/11
Y1 - 2024/3/11
N2 - Current prognostic tools for pneumonia predominantly focus on mortality, often neglecting other crucial outcomes such as the need for advanced respiratory support. The objective of this study was to develop and validate a tool that predicts the early risk of non-occurrence of respiratory deterioration or mortality. We conducted a single-center, retrospective cohort study involving hospitalized adult patients with community-acquired pneumonia (CAP) and acute hypoxic respiratory failure from January 2009 to December 2019 (n = 4379). We employed the gradient boosting machine (GBM) learning to create a model that estimates the likelihood of patients requiring advanced respiratory support (high-flow nasal cannula [HFNC], non-invasive mechanical ventilation [NIMV], and invasive mechanical ventilation [IMV]) or mortality during hospitalization. This model utilized readily available data, including demographic, physiologic, and laboratory data, sourced from electronic health records and obtained within the first 6 h of admission. Out of the cohort, 890 patients (25.2%) either required advanced respiratory support or died during their hospital stay. Our predictive model displayed superior discrimination and higher sensitivity (cross-validation C-statistic = 0.71; specificity = 0.56; sensitivity = 0.72) compared to the pneumonia severity index (PSI) (C-statistic = 0.65; specificity = 0.91; sensitivity = 0.24; P value < 0.001), while maintaining a negative predictive value (NPV) of approximately 0.85. These data demonstrate that our machine-learning model predicted the non-occurrence of respiratory deterioration or mortality among hospitalized CAP patients more accurately than the PSI. The enhanced sensitivity of this model holds the potential for reliably excluding low-risk patients from pneumonia clinical trials.
AB - Current prognostic tools for pneumonia predominantly focus on mortality, often neglecting other crucial outcomes such as the need for advanced respiratory support. The objective of this study was to develop and validate a tool that predicts the early risk of non-occurrence of respiratory deterioration or mortality. We conducted a single-center, retrospective cohort study involving hospitalized adult patients with community-acquired pneumonia (CAP) and acute hypoxic respiratory failure from January 2009 to December 2019 (n = 4379). We employed the gradient boosting machine (GBM) learning to create a model that estimates the likelihood of patients requiring advanced respiratory support (high-flow nasal cannula [HFNC], non-invasive mechanical ventilation [NIMV], and invasive mechanical ventilation [IMV]) or mortality during hospitalization. This model utilized readily available data, including demographic, physiologic, and laboratory data, sourced from electronic health records and obtained within the first 6 h of admission. Out of the cohort, 890 patients (25.2%) either required advanced respiratory support or died during their hospital stay. Our predictive model displayed superior discrimination and higher sensitivity (cross-validation C-statistic = 0.71; specificity = 0.56; sensitivity = 0.72) compared to the pneumonia severity index (PSI) (C-statistic = 0.65; specificity = 0.91; sensitivity = 0.24; P value < 0.001), while maintaining a negative predictive value (NPV) of approximately 0.85. These data demonstrate that our machine-learning model predicted the non-occurrence of respiratory deterioration or mortality among hospitalized CAP patients more accurately than the PSI. The enhanced sensitivity of this model holds the potential for reliably excluding low-risk patients from pneumonia clinical trials.
KW - Community-acquired pneumonia (CAP)
KW - advanced respiratory support
KW - machine learning
KW - mortality
KW - predictive modeling
UR - http://www.scopus.com/inward/record.url?scp=85187256242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85187256242&partnerID=8YFLogxK
U2 - 10.17305/bb.2023.9754
DO - 10.17305/bb.2023.9754
M3 - Article
C2 - 37795970
AN - SCOPUS:85187256242
SN - 2831-0896
VL - 24
SP - 337
EP - 345
JO - Biomolecules and Biomedicine
JF - Biomolecules and Biomedicine
IS - 2
ER -